Unlocking the power of translational medicine Unlocking the power of translational medicine, Published online: 18 February 2019; doi:10.1038/d41573-019-00030-xUnlocking the power of translational...
Paris, 14th March 2018 - OpenHealth Company is honoured at the Big Data Paris Innovation Awards. This award acknowledges and distinguishes the know-how and dynamics of OpenHealth Company, which has become a key player in the real-time processing of healthcare data.
The Big Data Paris show, held on the 12th and 13th of March, was an opportunity to highlight the recent challenges related to data democratisation and data processing. This is the 6th time that these Innovation Trophies, which reward the bold and innovative approaches of Big Data companies, have been bestowed. The Jury unanimously selected OpenHealth Company from among over 40 featured projects to receive Big Data’s 2018 “Coup de Cœur” prize. This powerfully underscores the French company’s expertise and innovative approach in the field of healthcare, where the challenges presented by Big Data and AI are considerable. Proof beyond a doubt that there are talents and companies already working in France to meet the challenges of mass data processing and artificial intelligence in the health sector.
Thus, the highly-anticipated report of the artificial intelligence mission led by mathematician and Essonne Deputy Cédric Villani (LREM) will be presented in late March and should certainly include the prospects for the health sector. Predictive models and AI capabilities offer promising opportunities for detecting and preventing the risk of hospitalisation for chronic patients and for developing precision medicine and many other applications. This is an area where OpenHealth Company intends to play a leading role.
The company markets essentially on-line data analysis services, specifically based on so-called "real life" data, to the drug industry and public health. Its web analytics platform model combines three main functions:
OpenHealth Company has European ambitions in the field of predictive medicine and supports the digital transformation of healthcare systems, the personalisation and real-time monitoring of care pathways, and the development of better understanding of diseases and their treatments.
OpenHealth Company, created in 2015 by Patrick Guérin, then president of Celtipharm, and Jean-Yves Robin, former director of ASIP Santé (the French agency responsible for public policy as regards digital healthcare attached to the Ministry of Health), is the French leader in the collection and real-time analysis of healthcare data. This expertise is based on the collection and aggregation of real-life data from many sources: outpatient healthcare product sales data (a panel of over 10,700 pharmacies), sector data, patient longitudinal data, medical data, international data, etc. The company offers its industrial and institutional customers new agile solutions and unique business support thanks to its multidisciplinary team (doctors, pharmacists, data scientists, market access experts, industry executives). OpenHealth Company, which employs around 50 people divided between its Paris headquarters and its production site in Vannes, achieved a turnover of €8 million in 2017 and, to finance its growth in France, concluded its first fundraising round in 2017 for nearly €5 million with the SISA fund managed by LBO France. The company is an accredited personal healthcare data host. More information on www.openhealth.fr.